CL2020001048A1 - Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) - Google Patents

Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)

Info

Publication number
CL2020001048A1
CL2020001048A1 CL2020001048A CL2020001048A CL2020001048A1 CL 2020001048 A1 CL2020001048 A1 CL 2020001048A1 CL 2020001048 A CL2020001048 A CL 2020001048A CL 2020001048 A CL2020001048 A CL 2020001048A CL 2020001048 A1 CL2020001048 A1 CL 2020001048A1
Authority
CL
Chile
Prior art keywords
antibodies against
monoclonal antibodies
against bcma
divisional request
divisional
Prior art date
Application number
CL2020001048A
Other languages
English (en)
Inventor
Minh Diem Vu
Klaus Strein
Oliver Ast
Marina Bacac
Camille Delon
Lydia Jasmin Duerner
Anne Freimoser-Grundschober
Christian Klein
Ekkehard Moessner
Samuel Moser
Pablo Umana
Tina Weinzierl
Original Assignee
Engmab Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engmab Sarl filed Critical Engmab Sarl
Publication of CL2020001048A1 publication Critical patent/CL2020001048A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS ANTICUERPOS CONTRA BCMA, MÉTODO DE PREPARACIÓN, COMPOSICIÓN QUE LOS COMPRENDE Y SU USO.
CL2020001048A 2015-08-03 2020-04-17 Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281) CL2020001048A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15179549 2015-08-03

Publications (1)

Publication Number Publication Date
CL2020001048A1 true CL2020001048A1 (es) 2020-08-28

Family

ID=53776451

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018000281A CL2018000281A1 (es) 2015-08-03 2018-01-31 Anticuerpos monoclonales contra bcma
CL2020001048A CL2020001048A1 (es) 2015-08-03 2020-04-17 Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2020002801A CL2020002801A1 (es) 2015-08-03 2020-10-28 Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2018000281A CL2018000281A1 (es) 2015-08-03 2018-01-31 Anticuerpos monoclonales contra bcma

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002801A CL2020002801A1 (es) 2015-08-03 2020-10-28 Anticuerpos monoclonales contra bcma (divisional de solicitud 201800281).

Country Status (30)

Country Link
US (3) US10683369B2 (es)
EP (2) EP3331910B1 (es)
JP (2) JP6682632B2 (es)
KR (1) KR20180042271A (es)
CN (1) CN108350073B (es)
AU (1) AU2016302881B2 (es)
BR (1) BR112018001955B1 (es)
CA (1) CA2992797A1 (es)
CL (3) CL2018000281A1 (es)
CO (1) CO2018001149A2 (es)
CY (1) CY1122804T1 (es)
DK (1) DK3331910T3 (es)
EA (2) EA036975B1 (es)
EC (1) ECSP18007905A (es)
ES (1) ES2777602T3 (es)
HK (1) HK1249114A1 (es)
HR (1) HRP20200390T1 (es)
HU (1) HUE048939T2 (es)
IL (1) IL257233B (es)
LT (1) LT3331910T (es)
MX (2) MX2018001398A (es)
NZ (1) NZ739252A (es)
PL (1) PL3331910T3 (es)
PT (1) PT3331910T (es)
RS (1) RS60030B1 (es)
SA (1) SA518390854B1 (es)
SG (1) SG10202007177XA (es)
SI (1) SI3331910T1 (es)
WO (1) WO2017021450A1 (es)
ZA (1) ZA201800435B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014004168A2 (pt) 2011-08-23 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
SG11201504497TA (en) 2013-02-26 2015-09-29 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
PE20170263A1 (es) 2014-08-04 2017-03-30 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
JP6708635B2 (ja) 2014-10-09 2020-06-10 エンクマフ エスアーエールエル ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
SG11201704056XA (en) 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
CN107849137B (zh) 2015-10-02 2021-11-26 豪夫迈·罗氏有限公司 双特异性抗ceaxcd3 t细胞活化性抗原结合分子
WO2017097723A2 (en) 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Treatment method
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
US20170233484A1 (en) 2016-02-17 2017-08-17 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
ES2947230T3 (es) 2016-03-22 2023-08-03 Hoffmann La Roche Moléculas biespecíficas para linfocitos T activadas por proteasa
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
SG11201903359RA (en) * 2016-11-02 2019-05-30 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
EP3577134A1 (en) 2017-01-31 2019-12-11 Novartis AG Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019053613A2 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
EP3694878A1 (en) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Combination treatment for cancer
JP2020533383A (ja) 2017-09-14 2020-11-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 癌の組合せ治療
CA3078799A1 (en) * 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
CA3079407A1 (en) 2017-10-18 2019-04-25 Novartis Ag Compositions and methods for selective protein degradation
US20200360431A1 (en) 2017-11-15 2020-11-19 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
CA3081125A1 (en) 2018-02-01 2019-08-08 Innovent Biologics (Suzhou) Co., Ltd. Fully humanized anti-b cell maturation antigen (bcma) single-chain antibody and use thereof
PE20211116A1 (es) 2018-02-08 2021-06-23 Genentech Inc Moleculas biespecificas de union al antigeno y metodos de uso
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
US11401336B2 (en) 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
US20210130483A1 (en) * 2018-03-26 2021-05-06 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
CN111936514A (zh) 2018-03-30 2020-11-13 美勒斯公司 多价抗体
EA202092830A1 (ru) * 2018-05-23 2021-04-08 Селджин Корпорейшн Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
EP3802611A2 (en) 2018-06-01 2021-04-14 Novartis AG Binding molecules against bcma and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
MX2021001524A (es) * 2018-08-08 2021-04-19 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso.
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
US20220364055A1 (en) 2018-08-31 2022-11-17 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN113286817A (zh) 2018-09-25 2021-08-20 哈普恩治疗公司 Dll3结合蛋白及使用方法
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
BR112021008055A2 (pt) 2018-10-31 2021-08-10 Glaxosmithkline Intellectual Property Development Limited métodos para determinar o prognóstico de câncer em um paciente, para prever uma resposta do paciente ao tratamento com uma proteína de ligação ao antígeno bcma, para selecionar a dose de uma proteína de ligação ao antígeno bcma e para diagnosticar câncer, composições farmacêuticas, kit e uso de uma proteína de ligação ao antígeno bcma para tratar câncer
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
WO2020219978A1 (en) 2019-04-25 2020-10-29 Celgene Corporation Bcma/cd3 bispecific trivalent t-cell engaging (tce) antibodies and their use to treat hematological malignancies
CN111269315B (zh) * 2019-06-19 2022-04-08 北京智仁美博生物科技有限公司 针对bcma的单克隆抗体
JP2022542088A (ja) * 2019-07-30 2022-09-29 シャンハイ ハンセン バイオメディカル カンパニー リミテッド 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
CN114502593A (zh) 2019-08-06 2022-05-13 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和相关方法
CN112574308A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
EP4023673A4 (en) * 2019-10-10 2023-03-15 Suzhou Qin Pharmaceuticals Co., Ltd. HUMANIZED MONOCLONAL ANTIBODY TARGETING BCMA AND HAVING A MONKEY/HUMAN CROSS-REACTIVITY
IL292704A (en) * 2019-11-05 2022-07-01 Bristol Myers Squibb Co Methods of treatment with antibodies against bcma and cd3
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
EP4085076A4 (en) * 2020-01-03 2024-01-24 Biosion Inc ANTIBODIES BINDING TO BCMA AND THEIR USES
TW202128769A (zh) * 2020-01-03 2021-08-01 大陸商信立泰（成都）生物技術有限公司 結合bcma的抗體及其用途
CN111234020B (zh) * 2020-01-23 2020-10-23 和铂医药(苏州)有限公司 一种bcma结合蛋白及其制备方法和应用
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
MX2022009784A (es) * 2020-02-12 2022-09-09 Bristol Myers Squibb Co Terapia anti-bcma en trastornos autoinmunes.
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2021222552A1 (en) 2020-04-30 2021-11-04 Celgene Corporation Methods of treating cytokine-related adverse events
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
WO2022035793A1 (en) * 2020-08-10 2022-02-17 Precision Biosciences, Inc. Antibodies and fragments specific for b-cell maturation antigen and uses thereof
JP2023538118A (ja) 2020-08-21 2023-09-06 ノバルティス アーゲー Ｃａｒ発現細胞のインビボ生成のための組成物及び方法
WO2022094245A1 (en) 2020-10-30 2022-05-05 Vor Biopharma, Inc. Compositions and methods for bcma modification
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
CN117396231A (zh) 2021-04-30 2024-01-12 新基公司 使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
CA3220227A1 (en) 2021-05-28 2022-12-01 Matthew Bruce Combination therapies for treating cancer
KR20240040786A (ko) 2021-08-03 2024-03-28 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 생물제약 조성물 및 안정한 동위원소 표지 펩티드 맵핑 방법
CN116745325A (zh) * 2021-08-16 2023-09-12 上海优替济生生物医药有限公司 Bcma靶向抗体、嵌合抗原受体及其应用
AR126838A1 (es) 2021-08-20 2023-11-22 Novartis Ag Métodos para preparar células que expresan receptores de antígeno quiméricos
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2023144702A1 (en) 2022-01-25 2023-08-03 Glaxosmithkline Intellectual Property Development Limited Combination therapy for cancer
WO2024031091A2 (en) 2022-08-05 2024-02-08 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3856559T2 (de) 1987-05-21 2004-04-29 Micromet Ag Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5273743A (en) 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU722668B2 (en) 1994-12-30 2000-08-10 King's College London Methods for producing immunoglobulins containing protection proteins in plants and their use
GB9501079D0 (en) 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
CA2288992C (en) 1997-04-30 2012-06-12 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
EP2364997A3 (en) 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PRODUCING A POLYPEPTIDE
DK1332209T3 (da) 2000-09-08 2010-03-29 Univ Zuerich Samlinger af repeatproteiner indeholdende repeatmoduler
WO2002030954A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Procede de purification d'un anticorps
BR0114475A (pt) 2000-10-06 2003-12-23 Kyowa Hakko Kogyo Kk Célula para a produção de composição de anticorpo
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
ES2337986T3 (es) 2001-08-10 2010-05-03 Aberdeen University Dominios de union de antigenos de peces.
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
EP1314741B1 (en) 2001-11-14 2007-03-07 Affimed Therapeutics AG Bispecific anti-CD19 x anti-CD16 antibodies and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
GB0230201D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Retargeting
PL222222B1 (pl) 2003-01-22 2016-07-29 Glycart Biotechnology Ag Sposób wytwarzania polipeptydu
WO2004076489A1 (en) 2003-02-25 2004-09-10 Medinnova As Modified antibody
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
DK2330121T3 (en) 2004-06-02 2014-12-15 Adalta Pty Ltd Binding moieties based on shark IgNar domains
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
RU2007145509A (ru) 2005-05-09 2009-06-20 Гликарт Биотехнологи Аг (Ch) Антигенсвязывающие молекулы, имеющие модифицированные fc-участки и измененное связывание с fc-рецепторами
KR20080068004A (ko) 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
SG192479A1 (en) 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
DK1940881T3 (en) 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2007121354A2 (en) 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
US20100150918A1 (en) 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
RU2561457C2 (ru) 2007-04-03 2015-08-27 Эмджен Рисерч (Мьюник) Гмбх Cd3-эпсилон-связывающий домен с межвидовой специфичностью
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2009090032A1 (en) 2008-01-15 2009-07-23 F. Hoffmann-La Roche Ag Afucosylated antibodies against ccr5 and their use
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
EP2283355A2 (en) 2008-04-25 2011-02-16 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
ME02485B (me) 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
DK2352763T4 (da) 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
JP5746040B2 (ja) 2008-12-03 2015-07-08 ゲンマブ エー／エス 定常領域の中に改変を有する抗体変種
HUE029619T4 (en) 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
HRP20231066T1 (hr) 2011-05-27 2023-10-27 Glaxo Group Limited Bcma (cd269/tnfrsf17) - vezujući proteini
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
CA2934436A1 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors

Also Published As

Publication number Publication date
RS60030B1 (sr) 2020-04-30
ZA201800435B (en) 2018-12-19
US20230322957A1 (en) 2023-10-12
ECSP18007905A (es) 2018-10-31
HUE048939T2 (hu) 2020-09-28
IL257233B (en) 2021-06-30
PL3331910T3 (pl) 2020-05-18
HRP20200390T1 (hr) 2020-06-12
CN108350073A (zh) 2018-07-31
EA202092435A3 (ru) 2021-06-30
JP6682632B2 (ja) 2020-04-15
CY1122804T1 (el) 2021-05-05
US20190352427A1 (en) 2019-11-21
SA518390854B1 (ar) 2020-12-07
MX2020009649A (es) 2020-10-08
MX2018001398A (es) 2018-05-28
EA036975B1 (ru) 2021-01-21
NZ739252A (en) 2023-12-22
EP3331910B1 (en) 2019-12-11
IL257233A (en) 2018-03-29
HK1249114A1 (zh) 2018-10-26
AU2016302881A1 (en) 2018-02-08
JP2018532766A (ja) 2018-11-08
EP3331910A1 (en) 2018-06-13
CN108350073B (zh) 2022-03-18
US10683369B2 (en) 2020-06-16
CO2018001149A2 (es) 2018-07-10
CL2020002801A1 (es) 2021-02-19
SI3331910T1 (sl) 2020-07-31
DK3331910T3 (da) 2020-03-16
BR112018001955B1 (pt) 2021-05-11
EA201890441A1 (ru) 2018-07-31
SG10202007177XA (en) 2020-09-29
PT3331910T (pt) 2020-03-24
KR20180042271A (ko) 2018-04-25
JP6903188B2 (ja) 2021-07-14
EA202092435A2 (ru) 2021-02-26
CA2992797A1 (en) 2017-02-09
ES2777602T3 (es) 2020-08-05
CL2018000281A1 (es) 2018-11-09
US20200283545A1 (en) 2020-09-10
JP2020109117A (ja) 2020-07-16
BR112018001955A2 (pt) 2018-09-18
LT3331910T (lt) 2020-03-25
WO2017021450A1 (en) 2017-02-09
EP3670535A1 (en) 2020-06-24
AU2016302881B2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
ECSP19026178A (es) Anticuerpos anti-pd-1 y sus usos
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
CO2019007288A2 (es) Anticuerpos anti-ox40 y sus usos
CL2020000281A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39 y métodos de uso de anticuerpos anti-cd39
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
BR112017023872A2 (pt) anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
CR20180320A (es) Compuestos inhibidores de la quinasa de union a tank
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
CR20160419A (es) Nuevos compuestos biciclicos
CL2018003087A1 (es) Síntesis de indazoles.
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
CR20200483A (es) Anticuerpos anti-hla-g y utilización de los mismos
EA201691648A1 (ru) Способ получения противогрибковых соединений
EA201691649A1 (ru) Способ получения противогрибковых соединений
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
EA201992027A1 (ru) Водный состав антитела против pd-l1
CO2019013718A2 (es) Anticuerpos anti-trkb